Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Fiona Ruiz, Tassja J. Spindler, Sumer Arthurs, Tiffany Jehng, Kate Widmann, Joseph M. Benoun, Yuanbin Ru, Aditi Mehta, Rajani Dinavahi, Jason A. Dubovsky, Cokey Nguyen

Blood (2022) 140 (Supplement 1): 4966–4967.

https://doi.org/10.1182/blood-2022-157709

Published: 2022

Journal Articles

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Tassja J Spindler, Fiona Ruiz, Tiffany Jehng, Hanna Ding, Norma Guzman-Becerra, Shahram Khanzadeh, Xiaoming Li, Laurence Gamelin, Jason A. Dubovsky, Cokey Nguyen

Blood (2022) 140 (Supplement 1): 7529–7530.

https://doi.org/10.1182/blood-2022-157673

Published: 2022

Journal Articles

Comprehensive Activation Profiling of the Tabelecleucel Library, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Therapy

Joseph M Benoun, Fiona J Ruiz, Kate Widmann, Tiffany Jehng, Tassja Spindler, Jay Abraham, Sumer Minne, Karen E Tracy, Daniel Munson, Vinith Thota, Arthur Wang, Johnathan Chuan, Matt Yedwabnick, Jason A. Dubovsky

Blood (2021) 138 (Supplement 1): 2809.

https://doi.org/10.1182/blood-2021-147708

Published: 2021

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Multiplexed Immunofluorescence (IF) Analysis and Gene Expression Profiling of Biopsies from Patients with Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) Treated with Lisocabtagene Maraleucel (liso-cel) in Transcend NHL 001 Reveal Patterns of Immune Infiltration Associated with Durable Response

David J. Reiss, PhD, Trevor Do, David Kuo, Vanessa E. Gray, N. Eric Olson, Chung-Wein Lee, Mary H. Young, PhD, Shradha Srinivasan, Falon D. Gray, DVM, DACVP, Brian Fox, Suzana Couto, Jason A. Dubovsky, PhD, Frank Schmitz, Kathryn Newhall

Blood (2019) 134 (Supplement_1): 202.

https://doi.org/10.1182/blood-2019-127683

Published: 2019

Journal Articles

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, William G. Wierda, MD PhD, Jason A. Dubovsky, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Alan Mitchell, MSc, Jerill Thorpe, BSc, Lin Yang, PhD, Kathleen A. Dorritie, MD

Blood (2018) 132 (Supplement 1): 300.

https://doi.org/10.1182/blood-2018-99-110462

Published: 2018

Journal Articles

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Ta-Ming Liu, Jennifer A. Woyach, Yiming Zhong, Arletta Lozanski, Gerard Lozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A. Jones, Joseph Flynn, Leslie A. Andritsos, Kami Maddocks, Samantha M. Jaglowski, Kristie A. Blum, John C. Byrd, Jason A. Dubovsky, Amy J. Johnson

Blood (2015) 126 (1): 61–68.

https://doi.org/10.1182/blood-2015-02-626846

Published: 2015

Includes: Supplemental data

Journal Articles

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

Shuai Dong, MS, Daphne Guinn, Jason A Dubovsky, PhD, Yiming Zhong, PhD, Amy Lehman, Jeff Kutok, MD, PhD, Jennifer A. Woyach, MD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2014) 124 (21): 3324.

https://doi.org/10.1182/blood.V124.21.3324.3324

Published: 2014

Journal Articles

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Yiming Zhong, PhD, Shuai Dong, MS, Kelsey Thornton, Anjali Mishra, PhD, Pierluigi Porcu, MD, Michael Bradshaw, Angelina Bisconte, Timothy Owens, Erik Verner, Ken Brameld, Jens Oliver Funk, MD, Ronald Hill, Amy J. Johnson, PhD, Jason A Dubovsky, PhD

Blood (2014) 124 (21): 272.

https://doi.org/10.1182/blood.V124.21.272.272

Published: 2014

Journal Articles

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

Shuai Dong, Daphne Guinn, Jason A. Dubovsky, Yiming Zhong, Amy Lehman, Jeffery Kutok, Jennifer A. Woyach, John C. Byrd, Amy J. Johnson

Blood (2014) 124 (24): 3583–3586.

https://doi.org/10.1182/blood-2014-07-587279

Published: 2014

Includes: Supplemental data

Journal Articles

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

Blood (2014) 123 (25): 3988–3998.

https://doi.org/10.1182/blood-2014-03-562231

Published: 2014

Includes: Supplemental data

Journal Articles

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Y. Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson

Blood (2014) 123 (8): 1207–1213.

https://doi.org/10.1182/blood-2013-07-515361

Published: 2014

Includes: Supplemental data

Journal Articles

Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model

Blood (2013) 122 (21): 292.

https://doi.org/10.1182/blood.V122.21.292.292

Published: 2013

Journal Articles

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

Jason A. Dubovsky, Danielle L. Chappell, Bonnie K. Harrington, Kitty Agrawal, Leslie A. Andritsos, Joseph M. Flynn, Jeffrey A. Jones, Michael E. Paulaitis, Brad Bolon, Amy J. Johnson, John C. Byrd, Natarajan Muthusamy

Blood (2013) 122 (19): 3308–3316.

https://doi.org/10.1182/blood-2013-05-504597

Published: 2013

Includes: Supplemental data

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD

Blood (2012) 120 (21): 183.

https://doi.org/10.1182/blood.V120.21.183.183

Published: 2012

Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Blood (2012) 120 (21): 775.

https://doi.org/10.1182/blood.V120.21.775.775

Published: 2012

Journal Articles

Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling

Danielle L Chappell, Jason A Dubovsky, Ph.D, Leslie A Andritsos, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2012) 120 (21): 3866.

https://doi.org/10.1182/blood.V120.21.3866.3866

Published: 2012

Journal Articles

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

John Powers, B.S., Eva Sahakian, Ph.D, Jason A Dubovsky, Ph.D, Tyler Farnum, Emmanuel Berchmans, B.S., Douglas G McNeel, MD, Barry S. Skikne, MD, Kyle J MacBeth, Rami S. Komrokji, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2012) 120 (21): 3828.

https://doi.org/10.1182/blood.V120.21.3828.3828

Published: 2012

Journal Articles

Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.

Rosa Lapalombella, PhD, Virginia Goettl, Katie Williams, Larissa Tangeman, Shruti Jha, Jason A Dubovsky, Ph.D, Danielle L Chappell, Amy J Johnson, PhD, Vincent Sandanayaka, Sharon Shechter, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, John C. Byrd, MD

Blood (2012) 120 (21): 2452.

https://doi.org/10.1182/blood.V120.21.2452.2452

Published: 2012

NARROW

Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Exploring the Impact of Humoral Immunogenicity with Tabelecleucel for the Treatment of EBV + PTLD Following HCT and SOT

Comprehensive Activation Profiling of the Tabelecleucel Library, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Therapy

Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation

Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Germinal Center Generation and Maintenance By T Follicular Helper Cells Is Required For The Development Of Chronic Gvhd Associated Bronchiolitis Obliterans In a Preclinical Model

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Lymphocyte Cytosolic Protein 1 (LCP1) Is a Membrane Associated Molecular Target in Chronic Lymphocytic Leukemia and Is Activated in Microenvironment Signaling

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only